Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Written by Biospace on November 14, 2022

New therapeutic addresses need in patients suffering with cold and refractory tumors.

Topics: Press Coverage

Comments